Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

Thumbnail
View/Open
Accepted version (458.4Kb)
Date
2016-12
ICR Author
Banerjee, Susana
Author
Vergote, I
Banerjee, S
Gerdes, A-M
van Asperen, C
Marth, C
Vaz, F
Ray-Coquard, I
Stoppa-Lyonnet, D
Gonzalez-Martin, A
Sehouli, J
Colombo, N
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients. Provided here is a review of the existing data and guidelines in the European Union, relating to recommendations, as well as considerations, for the referral of OC patients for BRCA genetic testing. Based on this review of newly updated guidance and up-to-date evidence, the following is recommended: all patients with invasive epithelial OC (excluding borderline or mucinous), including those with fallopian tube and peritoneal cancers, should be considered as candidates for referral for BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at diagnosis, although patients can be referred at any stage; retrospective testing should be offered to patients in long-term follow-up because of the implications for family members and individual future breast cancer risk; and germline BRCA testing of a blood/saliva sample should initially be conducted and, if negative, tumour tissue should be tested (to identify non-germline [somatic] BRCA PARPi therapy candidates).
URI
https://repository.icr.ac.uk/handle/internal/565
DOI
https://doi.org/10.1016/j.ejca.2016.10.006
Collections
  • Other ICR Research
Subject
Humans
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Piperazines
Phthalazines
DNA, Neoplasm
Antineoplastic Agents
DNA Mutational Analysis
Mutation
Germ-Line Mutation
Genes, BRCA1
Genes, BRCA2
Europe
Female
Practice Guidelines as Topic
Genetic Testing
Hereditary Breast and Ovarian Cancer Syndrome
Carcinoma, Ovarian Epithelial
Language
eng
Date accepted
2016-10-05
License start date
2016-12
Citation
European journal of cancer (Oxford, England : 1990), 2016, 69 pp. 127 - 134

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.